#United States #Vision Restoration #San Francisco, CA #Nanoscope #MCO-010

Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nanoscope Therapeutics Inc., an innovative biotechnology firm dedicated to creating advanced therapies for patients suffering from vision impairment, is preparing to make a significant presentation at the upcoming 44th Annual J.P. Morgan Healthcare Conference. Scheduled to take place from January 12-15, 2026, in San Francisco, CA, this event is a pivotal gathering for professionals in the healthcare sector.

Key Presentation Details

On January 12th, 2026, Sulagna Bhattacharya, the company's Chief Executive Officer, will take the stage from 11:30 to 11:55 AM PST to discuss the company's recent achievements and future plans. Her presentation will provide insights into Nanoscope's progress in developing its first-in-class optogenetic therapy, MCO-010, designed to treat patients suffering from retinitis pigmentosa (RP) and other retinal degenerative diseases.

Focus on Regulatory Progress and Clinical Trial Insights

During this presentation, Ms. Bhattacharya will emphasize the regulatory advancements Nanoscope has made, particularly in regards to the Biologics License Application (BLA) currently under rolling submission with the U.S. FDA. The company’s recent three-year follow-up results from the REMAIN study also demonstrated substantial and clinically relevant improvements in vision among patients after a single treatment with MCO-010. This data offers promising evidence for the therapy's potential as a standard treatment for RP, underscoring Nanoscope's commitment to improving patient outcomes in the realm of vision restoration.

Furthermore, the company plans to discuss the forward momentum in its clinical initiatives for Stargardt disease (SD) and the expected expansion into treating geographic atrophy (GA). These expansions indicate the therapeutic versatility of the MCO platform and its applicability to a broader patient population that suffers from severe vision loss due to various retinal conditions.

The Importance of the J.P. Morgan Healthcare Conference

Reflecting on the significance of the conference, Ms. Bhattacharya stated, "The J.P. Morgan Healthcare Conference is where science, capital, and conviction converge. With our rolling BLA underway, and important milestones across RP, Stargardt disease, and GA ahead, 2026 is a critical year for Nanoscope and an exciting time to partner with investors who share our mission to help patients, who have been left without treatment options, gain meaningful vision." This sentiment underscores the company's intent to attract strategic partnerships that can further propel its mission forward.

Nanoscope Therapeutics aims to facilitate in-person meetings during the conference to foster discussions with potential investors and stakeholders looking to understand the company’s innovative solutions. Interested parties are encouraged to schedule a meeting by contacting the Nanoscope team directly.

Breaking New Ground with the MCO Therapy

The MCO platform represents a significant advancement in the field of optogenetics, designed to restore vision in patients with various forms of photoreceptor degeneration. This novel therapy platform works by activating remaining retinal cells, thereby bypassing damaged photoreceptors and restoring some level of visual function. The treatment can be administered in-office and does not require extensive interventions, making it accessible to a wider range of patients.

Nanoscope Therapeutics is revolutionizing the landscape of vision care, aiming to provide safe and effective solutions that empower individuals suffering from debilitating eye conditions. As the company gears up for its presentation at the J.P. Morgan Healthcare Conference, it stands at the forefront of an exciting era in biotech, promising to reshape the future of vision restoration therapies.

For more details or inquiries, Nanoscope Therapeutics can be contacted via their official communication channels. Their commitment to unveil groundbreaking therapies positions them as a key player in the evolving healthcare landscape.